Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Fosifloxuridine nafalbenamide - Nucana BioMed

Next Previous
Drug Profile

Fosifloxuridine nafalbenamide - Nucana BioMed

Alternative Names: 5-Fluorouracil ProTide - NuCana; FUDR-phosphoramidate; NUC 3373

Latest Information Update: 26 Sep 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cardiff University
  • Developer NuCana
  • Class Amino acids; Antineoplastics; Fluorinated hydrocarbons; Naphthalenes; Pyrimidine nucleotides; Small molecules; Uracil nucleotides
  • Mechanism of Action DNA synthesis inhibitors; Thymidylate synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Colorectal cancer
  • Phase I/II Solid tumours
  • No development reported Breast cancer; Non-small cell lung cancer

Most Recent Events

  • 26 Sep 2025 No development reported - Phase-I for Non-small cell lung cancer (Combination therapy) (IV) (Nucana BioMed pipeline, September 2025)
  • 15 Jul 2025 Nucana terminates a phase I/II trial in Solid tumours (Late-stage disease, Inoperable/Unresectable, Second-line therapy or greater, Metastatic disease, Combination therapy) in United Kingdom, due to refinement of the pipeline strategy (IV) (NCT05714553)
  • 11 Nov 2024 Efficacy and adverse events data from the phase Ib/II trial in Solid tumours released by Nucana

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top